LEP and fatty liver disease: Indeed, when it was tested in obese/overweight individuals with the metabolic syndrome, rimonabant was found to effectively reduce food intake and body weight, reverse obesity-induced insulin and leptin resistance, decrease hepatic steatosis and liver injury, and improve glucose homeostasis and hyperlipidemias [[18], [19], [20],[49], [50], [51], [52]].